RAPT THERAPEUTICS INC (RAPT)
US75382E1091 - Common Stock
Noteworthy Monday Option Activity: RAPT, XPOF, ASTH
Monday's session: top gainers and losers
Let's take a look at the stocks that are in motion in today's session.
Discover the most active stocks in Monday's session. Stay informed about the stocks that are generating the most trading volume!
Monday's session: most active stocks
Why RAPT Therapeutics Stock Gained Over 100% On Monday?
RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are trading higher after the company disclosed a partnership with Shanghai Jemincare Pharmaceutical. The collaboration is for an exclusive license agreement to develop and commercialize RPT904, a novel anti-IgE monoclonal antibody worldwide, excluding mainland China, Hong Kong, Macau, and Taiwan. RPT904 is designed to provide a potential alternative to omalizumab (Xolair), addressing allergic conditions such as asthma and chronic spontaneous urticaria
What's going on in today's session
These stocks are moving in today's session
Which stocks are gapping on Monday?
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
RAPT Therapeutics Announces $150 Million Private Placement
RAPT Therapeutics Announces $150 Million Private Placement
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics...
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody
- RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high...
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics...
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Continues to advance preclinical pipeline, including next generation CCR4 compounds, and pursue licensing opportunities
Notable Wednesday Option Activity: STZ, WWW, RAPT
Noteworthy Monday Option Activity: TERN, RAPT, FBRT
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips RAPT Therapeutics (NASDAQ:RAPT) just reported results for the second quarter of...
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics...
Commit To Purchase RAPT Therapeutics At $2.50, Earn 13.4% Annualized Using Options
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024
RAPT stock results show that RAPT Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Oversold Conditions For RAPT Therapeutics
RAPT Therapeutics Reports First Quarter 2024 Financial Results
Company maintains solid cash position of $141.6 million
RAPT Therapeutics Reports First Quarter 2024 Financial Results
Company maintains solid cash position of $141.6 million...
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with...
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling.